Post by
NamesJeb on Oct 24, 2020 8:54am
Buyout framework
I was wondering if anyone here has much experience with what exactly the process would be if Ifenprodil does reach statistical significance and companies started making offers? What exactly would happen to share structure? Would it be a buyout, or partnership, and would the other ipf/chronic cough trial be effected from a shareholder perspective?
Comment by
TheBearInTheWoods on Oct 25, 2020 11:54pm
Without a patent pharma wouldn't waster their time, enjoy
Comment by
Proinvest2020 on Oct 26, 2020 6:27am
Bear in woods, Haven't they clearly stated that they have the intellectual property rights for ifenprodil's use for respiratory issues? if they don't why would they say so? Why would they spend all this time and effort to run these trials?
Comment by
Proinvest2020 on Oct 26, 2020 9:21am
Ahh ok... so filed for the rights... guess i heard what I wanted to hear. Not sure if there would be a reason to not grant the right to use it for resp. illness. Thats a big if ... Worth the risk for me if the drug works as expected. Not so Pro I guess..lol!
Comment by
TheBearInTheWoods on Oct 26, 2020 10:20am
The drug is already being manufactured and sold, has been since the 1979s. If there is success I would imagine mild success for AGN and huge success for the pharma companies already manufacturing the drug.
Comment by
Pandora on Oct 26, 2020 10:33am
Yes, you can purchase it relatively cheap in Japan right now.
Comment by
NamesJeb on Oct 26, 2020 12:04pm
Also patents expire after 20 years(give or take a year or so extension) Ifenprodil patent is long expired I believe.
Comment by
Raddnar on Oct 26, 2020 1:24pm
Your ignorance on how the FDA and other countries’ version of it work is outstanding. Instead of posting you should read.
Comment by
Raddnar on Oct 26, 2020 1:28pm
Don’t feed the bear. AGN is covered for ifenprodil.